On the basis of type, the humanized mouse model market is categorized into genetic and cell-based humanized mouse model. The genetic models segment is estimated to account for the largest share of the global humanized mouse model market, by type. The cell-based models segment is projected to grow at the highest CAGR between 2016 and 2021, owing to the growing applications of cell-based humanized mouse models. The cell-based mouse model segment is further segmented into CD34, PBMC, and BLT humanized mouse.
In 2016, the CD34 model segment is expected to command the largest share of the global cell-based humanized mouse model market and grow at the highest CAGR during the forecast period. CD34 mouse models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. Additionally, they are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.
On the basis of application, the humanized mouse model market is segmented into oncology, immunology & infectious diseases, neuroscience, toxicology, hematopoiesis, and other applications (which include rare diseases, graft-versus-host diseases, cardiovascular diseases, and regenerative medicine). In 2016, the oncology segment is expected to command the largest share of the market.
On the basis of end user, the humanized mouse model market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2016, the pharmaceutical & biotechnology companies segment is expected to command the largest share of the market.
Key players in the global humanized mouse model market include The Jackson Laboratory (U.S.), Taconic Biosciences, Inc. (U.S.), Harbour Antibodies BV (China), HuMurine Technologies, Inc. (U.S.), Vitalstar Biotechnology Co. Ltd. (China), Crown Bioscience, Inc. (U.S.), ingenious targeting laboratory (U.S.), Axenis S.A.S (France), TRANS GENIC, Inc. (Japan), genOway S.A. (France), and Horizon Discovery Group plc (U.K.).
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
